Table 3.
Relative effect sizes for odds of achieving glycemic target
| Regimen | Odds of achieving glycemic target (≤7%) | |||
|---|---|---|---|---|
| Random effects model | Fixed effect model | |||
| All vs. placebo | Exenatide QW vs. all | All vs. placebo | Exenatide QW vs. all | |
| Odds ratio (95% CrI) | Odds ratio (95% CrI) | Odds ratio (95% CrI) | Odds ratio (95% CrI) | |
| Placebo | N/A | 7.92 (0.76, 85.71) | N/A | 7.68 (3.86, 15.44)* |
| Dulaglutide 1.5 mg QW | 10.55 (0.68, 174.34) | 0.75 (0.06, 9.88) | 9.96 (4.80, 20.74)* | 0.77 (0.39, 1.53) |
| Liraglutide 1.8 mg QD | 10.38 (1.06, 108.20)* | 0.76 (0.10, 6.02) | 9.82 (5.17, 18.65)* | 0.78 (0.44, 1.41) |
| Liraglutide 1.2 mg QD | 5.76 (0.70, 49.75) | 1.38 (0.21, 8.95) | 5.48 (3.03, 9.94)* | 1.40 (0.83, 2.38) |
| Exenatide 10 µg BID | 3.75 (1.19, 13.71)* | 2.11 (0.17, 23.71) | 3.27 (2.28, 4.74)* | 2.35 (1.17, 4.73)* |
| Lixisenatide 20 µg QD | 2.91 (1.12, 7.83)* | 2.72 (0.31, 23.43) | 2.82 (2.14, 3.74)* | 2.72 (1.44, 5.16)* |
| Exenatide 5 µg BID | 2.45 (0.57, 12.07) | 3.23 (0.21, 46.76) | 2.16 (1.19, 3.89)* | 3.56 (1.50, 8.50)* |
| Exenatide 2 mg QW | 7.92 (0.76, 85.71) | N/A | 7.68 (3.86, 15.44)* | N/A |
BID twice daily, CrI credible interval, N/A not applicable, QD once daily, QW once weekly
* Statistically significant difference